{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:26:40Z","timestamp":1792193200408,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.thromres.2010.01.045","type":"journal-article","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T04:17:06Z","timestamp":1266380226000},"page":"5-11","source":"Crossref","is-referenced-by-count":194,"title":["Mechanisms of Estrogen-Induced Venous Thromboembolism"],"prefix":"10.1016","volume":"126","author":[{"given":"Svetlana N.","family":"Tchaikovski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2010.01.045_bib1","unstructured":"WHO scientific group meeting on cardiovascular disease and steroid hormone contraceptives. Wkly Epidemiol Rec 1997, 72:361\u2013363."},{"key":"10.1016\/j.thromres.2010.01.045_bib2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib3","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(61)91061-3","article-title":"Pulmonary embolism","volume":"18","author":"Jordan","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.1963.03060020091034","article-title":"Oral contraception and venous thrombosis","volume":"185","author":"Tyler","year":"1963","journal-title":"Jama"},{"key":"10.1016\/j.thromres.2010.01.045_bib5","doi-asserted-by":"crossref","unstructured":"Connell EB: Contraception in the prepill era. Contraception 1999, 59:7S-10S.","DOI":"10.1016\/S0010-7824(98)00130-9"},{"key":"10.1016\/j.thromres.2010.01.045_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2010.01.045_bib7","first-page":"32","article-title":"Clinical experience with the recently developed progestogens","volume":"36","author":"Skouby","year":"1991","journal-title":"Int J Fertil"},{"key":"10.1016\/j.thromres.2010.01.045_bib8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib9","doi-asserted-by":"crossref","unstructured":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995, 346:1582\u20131588.","DOI":"10.1016\/S0140-6736(95)91927-9"},{"key":"10.1016\/j.thromres.2010.01.045_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/bmj.326.7383.254","article-title":"Influence of the third generation pill controversy on prescriptions for oral contraceptives among first time users: population based study","volume":"326","author":"de Jong-van den Berg","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.thromres.2010.01.045_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(99)01257-X","article-title":"Venous thromboembolism among new users of different oral contraceptives","volume":"354","author":"Herings","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.160.1.49","article-title":"Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects","volume":"160","author":"Bloemenkamp","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2010.01.045_bib13","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"Bmj"},{"key":"10.1016\/j.thromres.2010.01.045_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1995.tb31386.x","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity","volume":"761","author":"Muhn","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.thromres.2010.01.045_bib15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(01)06522-9","article-title":"Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives","volume":"358","author":"Vasilakis-Scaramozza","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib16","first-page":"482","article-title":"Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?","volume":"81","author":"Odlind","year":"2002","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.thromres.2010.01.045_bib17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","article-title":"Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial","volume":"103","author":"Kemmeren","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.045_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/0002-9378(85)90664-7","article-title":"Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol","volume":"151","author":"Goebelsmann","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.thromres.2010.01.045_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2165\/00003495-199651020-00002","article-title":"Comparative pharmacology of newer progestogens","volume":"51","author":"Kuhl","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.thromres.2010.01.045_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","article-title":"A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways","volume":"84","author":"Tans","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-0037-1613958","article-title":"Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study","volume":"84","author":"Middeldorp","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0037-1613959","article-title":"Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives","volume":"84","author":"Meijers","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/AOG.0b013e3181626d1b","article-title":"Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial","volume":"111","author":"Johnson","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.thromres.2010.01.045_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X","article-title":"Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives","volume":"60","author":"Harris","year":"1999","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2010.01.045_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1538-7836.2009.03394.x","article-title":"Genetics of venous thrombosis","volume":"7","author":"Rosendaal","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib26","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood.V92.7.2353","article-title":"Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families","volume":"92","author":"Martinelli","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.045_bib27","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","article-title":"A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis","volume":"88","author":"Poort","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.045_bib28","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(05)80081-9","article-title":"Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study","volume":"342","author":"Koster","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(69)91955-2","article-title":"Venous thromboembolic disease and ABO blood type. A cooperative study","volume":"1","author":"Jick","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2007.03.007","article-title":"The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis","volume":"121","author":"Grunbacher","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2010.01.045_bib31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.90.3.1004","article-title":"Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C","volume":"90","author":"Dahlback","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thromres.2010.01.045_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2010.01.045_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.thromres.2005.07.022","article-title":"Endogenous or exogenous coagulation factor level and the response to activated protein C","volume":"118","author":"Gennari","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2010.01.045_bib34","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1538-7836.2005.01430.x","article-title":"van Hylckama Vlieg A, Tans G, et al: Determinants of the APTT- and ETP-based APC sensitivity tests","volume":"3","author":"de Visser","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2003.04443.x","article-title":"van Hylckama Vlieg A, Thomassen MC, et al: Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women","volume":"122","author":"Tans","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.01.045_bib36","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis","volume":"93","author":"de Visser","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.045_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","article-title":"Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism","volume":"130","author":"Rodeghiero","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2010.01.045_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1365-2141.2001.03089.x","article-title":"High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene","volume":"115","author":"Kamphuisen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.01.045_bib39","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V95.12.3678","article-title":"High levels of factor IX increase the risk of venous thrombosis","volume":"95","author":"van Hylckama Vlieg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.045_bib40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2010.01.045_bib41","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/j.1538-7836.2003.0543b.x","article-title":"High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly","volume":"1","author":"van Hylckama Vlieg","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib42","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2002-10-3188","article-title":"Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis","volume":"101","author":"Dahm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.01.045_bib43","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)10266-0","article-title":"Venous thrombosis: a multicausal disease","volume":"353","author":"Rosendaal","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib44","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/humupd\/5.6.672","article-title":"Biological coagulation findings in third-generation oral contraceptives","volume":"5","author":"Conard","year":"1999","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.thromres.2010.01.045_bib45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1160\/TH04-11-0762","article-title":"Effect of oral contraceptives on the anticoagulant activity of protein S in plasma","volume":"93","author":"Koenen","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2141.1995.tb05323.x","article-title":"Resistance to activated protein C in healthy women taking oral contraceptives","volume":"91","author":"Olivieri","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.01.045_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2141.1997.192707.x","article-title":"Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives","volume":"97","author":"Rosing","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.01.045_bib48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613145","article-title":"Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test","volume":"88","author":"Curvers","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2141.2001.03111.x","article-title":"Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial","volume":"115","author":"Hoibraaten","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.01.045_bib50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0002-9378(97)70289-8","article-title":"Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation","volume":"177","author":"Vandenbroucke","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.thromres.2010.01.045_bib51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1538-7836.2007.02824.x","article-title":"Coagulation factors and the protein C system as determinants of thrombin generation in a normal population","volume":"6","author":"Dielis","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib52","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography","volume":"98","author":"Tchaikovski","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2141.1988.tb04232.x","article-title":"Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception","volume":"68","author":"Malm","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.01.045_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1538-7836.2008.02863.x","article-title":"Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor","volume":"6","author":"van Vliet","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1538-7836.2008.02859.x","article-title":"The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1","volume":"6","author":"Dahm","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib56","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1538-7836.2008.03240.x","article-title":"Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice","volume":"7","author":"Tchaikovski","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib57","doi-asserted-by":"crossref","first-page":"27852","DOI":"10.1074\/jbc.270.46.27852","article-title":"Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C","volume":"270","author":"Rosing","year":"1995","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2010.01.045_bib58","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1538-7836.2009.03363.x","article-title":"Regulation of TFPI function by protein S","volume":"7","author":"Hackeng","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0010-7824(78)90012-4","article-title":"Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women","volume":"17","author":"Humpel","year":"1978","journal-title":"Contraception"},{"key":"10.1016\/j.thromres.2010.01.045_bib60","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.contraception.2006.02.002","article-title":"Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel","volume":"73","author":"Jick","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.thromres.2010.01.045_bib61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.AOG.0000250968.82370.04","article-title":"Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users","volume":"109","author":"Cole","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.thromres.2010.01.045_bib62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.contraception.2007.10.004","article-title":"Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables","volume":"77","author":"Kluft","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.thromres.2010.01.045_bib63","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.thromres.2008.04.022","article-title":"Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study","volume":"123","author":"Fleischer","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2010.01.045_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2261-6-40","article-title":"Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1","volume":"6","author":"Dahm","year":"2006","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.thromres.2010.01.045_bib65","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"van den Heuvel","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.thromres.2010.01.045_bib66","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0091270006297919","article-title":"Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive","volume":"47","author":"Devineni","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2010.01.045_bib67","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)04394-9","article-title":"del Mar Melero-Montes M: Risk of idiopathic venous thromboembolism in users of progestagens alone","volume":"354","author":"Vasilakis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/13625189909064007","article-title":"Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women","volume":"4","author":"Heinemann","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.thromres.2010.01.045_bib69","doi-asserted-by":"crossref","unstructured":"Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998, 57:315\u2013324.","DOI":"10.1016\/S0010-7824(98)00041-9"},{"key":"10.1016\/j.thromres.2010.01.045_bib70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1160\/TH08-09-0621","article-title":"The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC)","volume":"101","author":"van Vliet","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0268-960X(99)90019-X","article-title":"Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?","volume":"13","author":"Walker","year":"1999","journal-title":"Blood Rev"},{"key":"10.1016\/j.thromres.2010.01.045_bib72","unstructured":"WHO: Medical eligibility criteria for contraceptive use."},{"key":"10.1016\/j.thromres.2010.01.045_bib73","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/humrep\/deh612","article-title":"Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens","volume":"20","author":"van Vliet","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.thromres.2010.01.045_bib74","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2010.01.045_bib75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2141.1999.01302.x","article-title":"Acquired APC resistance and oral contraceptives: differences between two functional tests","volume":"105","author":"Curvers","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.01.045_bib76","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1538-7836.2004.00894.x","article-title":"Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives","volume":"2","author":"Alhenc-Gelas","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.01.045_bib77","doi-asserted-by":"crossref","unstructured":"The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003, 67:173-185.","DOI":"10.1016\/S0010-7824(02)00476-6"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384810001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384810001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T20:59:22Z","timestamp":1590613162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384810001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0049384810001003"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2010.01.045","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}